NASDAQ:CTKB

Cytek Biosciences (CTKB) Stock Price, News & Analysis

Cytek Biosciences logo
$6.11 -0.21 (-3.39%)
Closing price 03:58 PM Eastern
Extended Trading
$6.14 +0.03 (+0.47%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Cytek Biosciences Stock (NASDAQ:CTKB)

Advanced

Key Stats

Today's Range
$5.99
▼
$6.39
50-Day Range
$4.61
▼
$6.32
52-Week Range
$3.31
▼
$6.39
Volume
1.34 million shs
Average Volume
1.10 million shs
Market Capitalization
$798.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.67
Consensus Rating
Hold

Company Overview

Cytek Biosciences develops, manufactures and sells cell analysis instruments and related products used by researchers and clinical laboratories. Its systems use flow cytometry to analyze cells and other particles, supporting work in areas such as immunology, oncology and infectious disease research.

The company’s product portfolio includes the Aurora and Northern Lights spectral flow cytometry systems and Amnis imaging flow cytometers. Cytek also offers reagents, software, technical support and other services that help customers prepare samples, collect and interpret data, and maintain their instruments.

Headquartered in Fremont, California, Cytek serves customers in North America and international markets, including Europe and Asia, through a combination of direct sales and distribution partners. Its business builds on decades of experience in developing cell analysis technologies.

AI Generated. May Contain Errors.

Cytek Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
32nd Percentile Overall Score

CTKB MarketRank™: 
1.607778690765 of 5 stars

Cytek Biosciences scored higher than 32% of companies evaluated by MarketBeat, and ranked 718th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Cytek Biosciences has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

  • Downside Risk

    Cytek Biosciences has a consensus price target of $5.67, representing about 7.5% downside from its current price of $6.13.

  • Amount of Analyst Coverage

    Cytek Biosciences has only been the subject of 2 research reports in the past 90 days.

  • Read more about Cytek Biosciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Cytek Biosciences are expected to grow in the coming year, from ($0.28) to ($0.11) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Cytek Biosciences is -9.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Cytek Biosciences is -9.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Cytek Biosciences has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.50% of the float of Cytek Biosciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Cytek Biosciences has a short interest ratio ("days to cover") of 3.56, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Cytek Biosciences has recently decreased by 6.89%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Cytek Biosciences does not currently pay a dividend.

  • Dividend Growth

    Cytek Biosciences does not have a long track record of dividend growth.

  • News Sentiment

    Cytek Biosciences has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Cytek Biosciences this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    1 people have added Cytek Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Cytek Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.36% of the stock of Cytek Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    69.46% of the stock of Cytek Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Cytek Biosciences' insider trading history.
Receive CTKB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytek Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CTKB Stock News Headlines

Cytek Biosciences to Participate in Upcoming Investor Conferences
Cytek Biosciences (CTKB) & Its Rivals Financial Review
A Bill Would Reprice America's Gold at Market Value
The US government still values its gold at $42 an ounce, a price Congress set in 1973. Gold trades above $4,000 today, leaving a trillion-dollar gap on the books. A bill now moving through Congress would require the Treasury to reprice America's gold at true market value. Companion legislation would trigger the first full audit of US reserves in over 65 years.tc pixel
Cytek Biosciences (CTKB) Q3 2026 Earnings Call Transcript
See More Headlines

CTKB Stock Analysis - Frequently Asked Questions

Cytek Biosciences' stock was trading at $5.05 at the start of the year. Since then, CTKB shares have increased by 21.3% and is now trading at $6.1250.

Cytek Biosciences, Inc. (NASDAQ:CTKB) issued its quarterly earnings data on Wednesday, November, 4th. The company reported ($0.05) EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.02. The business had revenue of $53.23 million for the quarter, compared to analyst estimates of $53.05 million. Cytek Biosciences had a negative trailing twelve-month return on equity of 13.13% and a negative net margin of 39.10%.
Read the conference call transcript
.

Cytek Biosciences' Board of Directors approved a stock repurchase plan on Monday, December 30th 2024, which allows the company to repurchase $50 million in outstanding shares, according to EventVestor. This means that the company could reacquire up to 5.9% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board believes its stock is undervalued.

Cytek Biosciences (CTKB) raised $248 million in an initial public offering on Thursday, July 22nd 2021. The company issued 14,564,635 shares at a price of $16.00-$18.00 per share.

Cytek Biosciences' top institutional shareholders include Boston Partners (4.99%), State Street Corp (1.95%), Russell Investments Group Ltd. (1.87%) and Goldman Sachs Group Inc. (1.78%). Insiders that own company stock include Ming Yan, Patrik Jeanmonod and William D Mccombe.
View institutional ownership trends
.

Shares of CTKB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Cytek Biosciences investors own include Micron Technology (MU), SoFi Technologies (SOFI), Kinross Gold (KGC), UiPath (PATH), Taiwan Semiconductor Manufacturing (TSM), Palantir Technologies (PLTR) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/04/2026
Today
11/20/2026
38th Annual Healthcare Conference
12/02/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Life Sciences Tools & Services
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:CTKB
CIK
1831915
Fax
N/A
Employees
703
Year Founded
1992

Price Target and Rating

High Price Target
$7.00
Low Price Target
$5.00
Potential Upside/Downside
-7.2%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.63)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$66.54 million
Net Margins
-39.10%
Pretax Margin
-19.24%
Return on Equity
-13.13%
Return on Assets
-9.56%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.46
Quick Ratio
3.84

Sales & Book Value

Annual Sales
$201.49 million
Price / Sales
3.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.46 per share
Price / Book
2.48

Miscellaneous

Outstanding Shares
130,780,000
Free Float
117,235,000
Market Cap
$798.54 million
Optionable
Optionable
Beta
1.15

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NASDAQ:CTKB) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners